Perrigo Company Announces Appointment Of New Board Of Directors Member

    Perrigo Company Announces Appointment Of New Board Of Directors Member

PR Newswire

ALLEGAN, Mich., Nov. 6, 2012

ALLEGAN, Mich., Nov. 6, 2012 /PRNewswire/ --The Perrigo Company (Nasdaq:
PRGO;TASE) today announced that its Board of Directors has appointed Jacqualyn
A. Fouse, Ph.D. as a new director of the Company.

(Logo: )

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "Jackie's
outstanding background has served her well in leadership roles at several
pharmaceutical and healthcare companies. Her broad business and strategic
acumen will allow her to make excellent contributions to our Board. We are
pleased to welcome Jackie to the Perrigo Board of Directors."

Jacqualyn A. Fouse, 51, has served as Executive Vice President and Chief
Financial Officer of Celgene Corporation, a leading global biopharmaceutical
company, since September of 2010. From July 2007 until September 2010, she
previously served as Chief Financial Officer for Bunge Ltd., a leading global
agribusiness and food company. From 2002 to July 2007, Ms. Fouse served as
Senior Vice President, Chief Financial Officer and Corporate Strategy, at
Alcon Laboratories, a leading eye care company. Prior to Alcon Laboratories,
Ms. Fouse was Chief Financial Officer of Swissair Group in Switzerland, 2001 –
2002, and she was Group Treasurer of Nestle S.A. in Switzerland from 1999 to
2001. Ms. Fouse held various senior level financial positions in both the U.S.
and Switzerland with both Alcon and Nestle form 1986 to 1999. She also held
positions with LTV Aerospace and Defense and Celanese Chemical Company from
1983 to 1986. Ms. Fouse currently serves on the Board of Dick's Sporting
Goods, a leading U.S. retailer of sporting goods and athletic apparel. 

From its beginnings as a packager of generic home remedies in 1887, Perrigo
Company, based in Allegan, Michigan, has grown to become a leading global
provider of quality, affordable healthcare products. The Company develops,
manufactures and distributes over-the-counter ("OTC") and generic prescription
("Rx") pharmaceuticals, nutritional products and active pharmaceutical
ingredients ("API") and is the world's largest manufacturer of OTC
pharmaceutical products for the store brand market. Perrigo's mission is to
offer uncompromised "quality, affordable healthcare products", and it does so
across a wide variety of product categories primarily in the United States,
United Kingdom, Mexico, Israel and Australia, as well as certain other markets
throughout the world, including Canada, China and Latin America. Visit Perrigo
on the Internet (

Note: Certain statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections. While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 30, 2012, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Perrigo Company

Contact: Arthur J. Shannon, Vice President, Investor Relations and
Communication, +1-269-686-1709,, or Bradley Joseph,
Senior Manager, Investor Relations and Communication, +1-269-686-3373,
Press spacebar to pause and continue. Press esc to stop.